{"id":"W4399737405","doi":"10.1200/jco.2024.42.16_suppl.tps3174","title":"First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Olaparib; Medicine; Poly ADP ribose polymerase; Cancer research; Synthetic lethality; Polymerase; Homologous recombination; DNA repair; PARP1; Pharmacology; DNA; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001504027,0.001960323,0.00232384,0.0004566919,0.0004027689,0.001610316,0.001174728,0.0018708,0.01164792],"category_scores_gemma":[0.0007076396,0.0007610364,0.001804074,0.0003779864,0.00104685,0.001333847,0.0004973761,0.003599313,0.001835471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082491,"about_ca_system_score_gemma":0.002086465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007770635,"about_ca_topic_score_gemma":0.002828485,"domain_scores_codex":[0.9995207,0.0001686914,0.00002140244,0.0001154371,0.00005047683,0.0001232394],"domain_scores_gemma":[0.9993492,0.00007321001,0.0001218843,0.00007805118,0.00005148723,0.0003261867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4474773,0.2220758,0.00409048,0.004023291,0.003048241,0.0007299996,0.0003833204,0.002508737,0.09205193,0.0008325138,0.0189402,0.2038382],"study_design_scores_gemma":[0.281702,0.6867377,0.004443132,0.0001103787,0.001003173,0.0007376678,0.0001126085,0.0007274519,0.009652585,0.0003565045,0.01437615,0.00004064295],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9460897,0.0206026,0.003826491,0.001679399,0.001208034,0.01096461,0.006573903,0.0005043384,0.008550905],"genre_scores_gemma":[0.9338605,0.01391116,0.006899896,0.004874199,0.0008334416,0.008691371,0.008207929,0.0001919632,0.02252958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01164792,"threshold_uncertainty_score":0.03896612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07941985966849405,"score_gpt":0.4509766338176114,"score_spread":0.3715567741491174,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}